Ro BodyvsPlushCare Weight Loss

Ro Body itself is a service layer, not a drug. You complete an online intake, a licensed clinician reviews your history, and, if appropriate, prescribes an FDA-approved GLP-1 (or dual GLP-1/GIP) medication such as Wegovy or Ozempic (semaglutide) or Zepbound (tirzepatide). These medicines mimic gut hormones that signal fullness to the brain, slow stomach emptying, and reduce appetite and food cravings, so most people eat less and lose weight. Ro layers on monthly provider check-ins, unlimited messaging, registered-nurse coaching, a behavior-change curriculum, dose-titration support, and an insurance concierge that submits prior authorizations to help you pursue coverage.

PlushCare itself is a telehealth platform, not a drug. You book a video visit with a board-certified physician who reviews your history, orders an obesity lab panel (typically CBC, a metabolic panel, lipids, A1C, TSH, and insulin, drawn through a lab such as Quest), and, if appropriate, prescribes a GLP-1 medication sent to your pharmacy. The medications work by mimicking gut hormones: semaglutide (Wegovy/Ozempic) activates GLP-1 receptors, while tirzepatide (Zepbound/Mounjaro) activates both GLP-1 and GIP receptors. They slow stomach emptying, reduce appetite, and increase fullness, so you tend to eat less and lose weight.

Ro cites average weight loss of roughly 15% of body weight over a year, a figure that tracks the medications' pivotal trials rather than a separate Ro study. In the STEP 1 trial (Wilding et al., NEJM 2021; n=1,961), once-weekly semaglutide 2.4 mg (Wegovy) produced a mean 14.9% weight loss at 68 weeks versus 2.4% for placebo, with 86.4% of participants losing at least 5%. For tirzepatide (Zepbound), the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022; n=2,539) showed mean losses of 16.0%, 21.4%, and 22.5% at the 5, 10, and 15 mg doses versus 2.4% for placebo over 72 weeks. These results reflect the medication combined with lifestyle change, and weight tends to return after stopping. Individual results vary.

PlushCare does not run its own trials; efficacy comes from the medications it prescribes. In the STEP 1 trial (NEJM 2021, 1,961 adults without diabetes), once-weekly semaglutide 2.4 mg (Wegovy) produced a mean 14.9% body-weight loss at 68 weeks versus 2.4% for placebo, with about 50.5% of users losing at least 15% of their body weight. In the SURMOUNT-1 trial (NEJM 2022, 2,539 adults), tirzepatide (Zepbound) produced mean reductions of about 16.0%, 21.4%, and 22.5% at the 5 mg, 10 mg, and 15 mg doses over 72 weeks, versus roughly 2.4% for placebo. Results depend on reaching and staying on an effective dose, and weight tends to return if the medication is stopped. Compounded versions are not FDA-approved and have not been tested for the same bioequivalence, so results with them may differ.

The most common side effects come from the GLP-1 medication, not the platform: nausea, vomiting, diarrhea, constipation, stomach pain, indigestion, gas, fatigue, and headache. These are usually mild to moderate, worst when starting or raising the dose, and tend to ease over time. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems and gallstones, kidney problems from dehydration, low blood sugar (especially if combined with insulin or a sulfonylurea), and, rarely, serious allergic reactions. Wegovy, Ozempic, and Zepbound carry an FDA boxed warning for thyroid C-cell tumors seen in rodents; whether this risk applies to humans is unknown. Stop the medication and seek care for severe stomach pain.

The side effects are those of the GLP-1 drugs themselves, not the platform. The most common are gastrointestinal: nausea, vomiting, diarrhea, constipation, and bloating, usually worst when starting or increasing the dose and often easing over time. Less common but serious risks include pancreatitis, gallbladder problems (including gallstones), and dehydration-related kidney injury from severe vomiting. These drugs carry an FDA boxed warning about thyroid C-cell tumors seen in rodents (the relevance to humans is unconfirmed, but they are contraindicated with a history of MTC or MEN 2). Tell your PlushCare doctor about severe or persistent abdominal pain, which can signal pancreatitis, and seek urgent care if it is intense.

As of 2026, Ro Body membership is about $45 the first month and roughly $145/month after, and is lower if you prepay annually (Ro's own site has listed figures closer to $39 first month and $149/month month-to-month, so confirm the current price at checkout). The membership fee is generally not covered by insurance, though HSA/FSA funds may apply. Medication is billed separately and is the bigger variable. If your insurance covers brand Wegovy or Zepbound, savings cards can bring your out-of-pocket cost down to as little as $0 to $25/month. Without coverage, cash-pay options through programs like NovoCare and LillyDirect have run roughly $300 to $500/month for self-pay vials or pens in 2026 (with introductory pricing as low as ~$199 for early Wegovy fills), and Ro advertises additional prepay savings. Confirm your specific drug, dose, and coverage before committing, because total out-of-pocket varies widely.

As of 2026, PlushCare charges a membership of about $19.99/month (often with a free first month) or roughly $99/year, plus consultation fees: about $129 per visit without insurance, or a copay (often $30 or less) with in-network insurance. These fees cover only the platform and doctor; the medication is billed separately. Brand-name GLP-1s can reach roughly $1,000+ per month at full retail if insurance denies coverage, but PlushCare also advertises promotional cash-pay brand pricing at times (for example, Ozempic and Wegovy near $199/month for the first two months, then higher) and offers compounded semaglutide in eligible states at around $149/month for the lowest dose and about $299/month for higher doses, which is paid out of pocket and does not run through insurance. PlushCare can attempt prior authorization for brand drugs, but GLP-1 coverage is never guaranteed and the process can take up to about two weeks. Confirm current pricing at signup, since promotional rates change.

Generally for US adults with obesity (BMI 30+) or overweight (BMI 27+) plus a weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol, who want medication-supported weight loss. Not appropriate for, and the underlying GLP-1 drugs are contraindicated in, anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or with a prior serious hypersensitivity reaction to the drug. Not for use in pregnancy or breastfeeding, and clinicians use caution with a history of pancreatitis, gallbladder disease, or severe gastrointestinal disorders. A clinician makes the final call, and some applicants are found ineligible.

PlushCare's program is for US adults who medically qualify for a GLP-1: generally a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. These drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and should not be used by people with a prior serious reaction to them. They are not recommended in pregnancy or breastfeeding, and people with a history of pancreatitis, gallbladder disease, gastroparesis or other severe GI disorders, diabetic retinopathy, or significant kidney impairment need careful physician evaluation. Final eligibility is decided by the prescribing doctor, not automatically.